MRK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Merck & Co Inc (MRK) is not a strong buy for a beginner, long-term investor at this moment. Despite positive analyst ratings and a solid pipeline, the current technical indicators, insider selling, and cautious congress trading activity suggest a hold position. The stock's recent financial performance shows growth in revenue but declining net income and EPS, which may concern long-term investors. Additionally, the pre-market price is slightly down, and options data indicates bearish sentiment. It may be better to wait for clearer bullish signals or improved financial trends before investing.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 38.092, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its support level (S1: 118.992), which could indicate potential downside risk.
FDA approval of Merck Animal Health's JAK inhibitor Numelvi, which could drive future revenue growth.
Analysts are optimistic about Merck's pipeline and its ability to navigate Keytruda's patent cliff.
Multiple analysts have raised price targets, with some as high as $150.
Insider selling has increased significantly (2945.40%), which could indicate lack of confidence from insiders.
Congress trading data shows 4 sale transactions and no purchases, reflecting cautious sentiment.
Weak Q4 financial performance with declining net income (-20.84%) and EPS (-19.59%).
In Q4 2025, revenue grew by 4.97% YoY to $16.4B, but net income dropped by 20.84% YoY to $2.96B, and EPS fell by 19.59% YoY to $1.19. Gross margin improved to 79.73%, up 4.54% YoY, but overall profitability metrics are declining.
Analysts are broadly positive on MRK, with multiple firms initiating or maintaining Buy/Outperform ratings and raising price targets. The highest price target is $150, and the consensus is optimistic about the company's pipeline and ability to manage Keytruda's loss of exclusivity.
